Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation

Expert Opin Drug Saf. 2024 May 3. doi: 10.1080/14740338.2024.2351462. Online ahead of print.ABSTRACTINTRODUCTION: Nowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient's clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personalized approach. In this scenario, major knowledge on psoriasis pathogenesis led to the development of deucravacitinib, an orally administered selective TYK2 inhibitor.AREAS COVERED: The aim of this manuscript is to review current literature on the effectiveness and safety of deucravacitinib in psoriasis to offer readers a wide perspective. The current English literature was analyzed using the PubMed, Google Scholar, Embase, Cochrane Skin, and clinicaltrials.gov databases, selecting the most relevant manuscripts.EXPERT OPINION: Deucravacitinib appears to be an innovative weapon for the management of moderate to severe psoriasis. Despite its efficacy and safety profiles have been revealed by RCTs, real-life data are still scant. Certainly, deucravacitinib broadens the range of therapeutic alternatives for psoriasis patients, thus enhancing the holistic and personalized approach required for the treatment of this disease.PMID:38699874 | DOI:10.1080/14740338.2024.2351462
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research